

## Updates on Alberta Vaccine Inventory (AVI) Compliance Requirements, Non-mRNA COVID-19 Vaccine Availability, and Extension to Expiry Dates for Paxlovid

### A. Alberta Vaccine Inventory (AVI) Compliance Requirements

#### Alberta Vaccine Inventory (AVI) Responsibilities and Expectations for Compliance

To safeguard vaccine accountability and visibility, the AVI system is used for inventory management for provincially funded vaccines. The AVI Responsibilities & Expectations for Compliance document outlines the mandatory weekly AVI responsibilities to receive provincially funded vaccine. Pharmacies must ensure that there are no outstanding transfers to receive or reject **and** reconcile AVI inventory using the Submit Inventory button every week to remain compliant. Compliance is reported to the pharmacies through the monthly compliance report. *The reporting of compliance status to each pharmacy will be reinstated in July 2023.*

AVI registration is required in order to participate in Alberta Immunization Programs. To register or update an AVI account, select the Register button on the AVI homepage (<https://vimsavi.alberta.ca/prod/>).

#### I've registered for AVI, now what?

Please visit the AVI homepage and access the AVI Responsibilities & Expectations document found on <https://vimsavi.alberta.ca/prod/login.jsp>.

You must access the AVI system to

- **receive transfers of vaccine** from your pharmacy wholesale distributor. The wholesaler will have 48 business hours to complete the transfer in AVI; and
- **reconcile your inventory** on a weekly basis. To fulfill reporting required by Alberta Health, a physical count of your on-hand quantities and a reconciliation amount must be completed in AVI once a week (ideally Mondays by 9 p.m.).

**AVI Reconciliation** can be done any day of the week **EXCEPT** Wednesdays and Thursdays.

The on-hand quantities reported in AVI will be used to manage vaccine inventory in the province. Accuracy is essential to managing the distribution and allocation of all vaccine in the province.

Please visit the User Guides and Training section on the AVI homepage for all how-to training materials. for

- [Pharmacy AVI Training \(PDF\)](#)
- [Receive or Reject an Order or Transfer QRG](#)
- [Inventory Reconciliation QRG](#)

*continued next page*

*continued from previous page*

### AVI Compliance Reports and Process

AVI monthly compliance reports will resume in **July 2023**. These reports include a non-compliant events table that outlines which non-compliant events have impacted their AVI compliance rate. Facilities are responsible for reviewing the monthly compliance emails to ensure AVI compliance is met.

The following steps will occur for pharmacies that are not compliant.

**First occurrence:** Pharmacies will receive an Active (Under Review) status after one month of AVI non-compliance. Pharmacies that receive an Active (Under Review) status must meet the minimum AVI compliance rate by the next reporting month to avoid a Frozen (1 Month) suspension from receiving provincially funded vaccine.

**Second occurrence:** Pharmacies receive a Frozen (1 Month) suspension after two consecutive months of AVI non-compliance. Pharmacies that receive a suspension are unable to order provincially funded vaccine during the suspension period. Pharmacies that receive a Frozen (1 Month) suspension must meet the minimum AVI compliance rate by the next reporting month to avoid a Frozen (6 Month) suspension.

**Third occurrence:** Pharmacies receive a Frozen (6 Month) suspension after three consecutive months of AVI non-compliance. Pharmacies that receive a suspension are unable to order and receive provincially funded vaccine during the suspension period. To be eligible to resume participating in the provincially funded vaccine program at the end of the suspension period, pharmacies must continue to complete the AVI responsibilities until AVI inventory has been depleted and there are no outstanding transfers to receive or reject. Pharmacies must contact [health.avi@gov.ab.ca](mailto:health.avi@gov.ab.ca) to request to reinstate deliveries at the end of the suspension period. Follow the directions in the Frozen (6 Month) email notification to reinstate deliveries.

Please note that with the grace period being lifted in July, pharmacies that have low compliance rates could receive a **Frozen (1 Month) suspension in October**, which could impact influenza vaccine distribution. If the low compliance leads to a **Frozen (6 Month) suspension**, it will impact the pharmacy's participation in the 2023-2024 Influenza Immunization Program.

Further information regarding non-compliant events and suspensions can be found on the FAQ portion of the AVI Responsibilities & Expectations document found on the AVI Login page: <https://vimsavi.alberta.ca/prod/login.jsp>.

### B. Non-mRNA COVID-19 Vaccine Availability

Pharmacies should no longer refer patients to AHS for administration of non-mRNA COVID-19 vaccines. As of July 1, there are no non-mRNA vaccines available to Albertans regardless of need or reason. Janssen COVID-19 vaccine has been withdrawn from the market and the Novavax COVID-19 vaccine doses have all expired. For more information on COVID-19 vaccines, please visit Alberta Health's vaccine website at <https://www.alberta.ca/covid19-vaccine.aspx>.

### C. Extension to Expiry Dates for Paxlovid Standard and Paxlovid Renal packs

Pfizer is correcting extended expiry dates previously provided in January 2023 for select lots of Paxlovid standard dose pack (DIN: 02524031) and moderate renal impairment dose pack (DIN: 02527804). The table below details the lots affected and the corrected extended expiry dates.

Pharmacy teams should check all on-hand inventory for affected lots and update accordingly.

**Please note that some expiry dates are shorter than labelled on the package, so critical attention to the matter is required.**

**Please verify the expiration dates of Paxlovid prior to dispensing.**

*continued next page*

# PHARMACY BENEFACT

continued from previous page

Dose Pack	Lot(s)#	Labelled Expiry Date	Corrected Extended Expiry Date
<b>PAXLOVID (300 mg nirmatrelvir (2 x 150 mg); 100 mg ritonavir)</b>	FT3540	2022-08-31	2023-07-31
	FX4437, FX4444	2023-01-31	2023-07-31
	FX8106	2023-01-31	2023-08-31
	FX7185	2023-01-31	2023-09-30
	GA6769, GA6205, GA6761	2023-02-28	2023-12-31
	GC2133, GC2886	2023-02-28	2024-01-31
	GC8177	2023-02-28	2024-02-29
	GD4585, GC5723, GC5720	2023-03-31	2024-01-31
	GA3793, GD1181	2023-03-31	2023-11-30
	GD1183	2023-03-31	2024-02-29
	GD4677, GD8410, GD8409, GC8182, GC8181	2023-04-30	2024-03-31
	GD8407, GD4673, GD4670, GD4671, GD4669, GC5733, GD4678	2023-04-30	2024-02-29
	GG2189, GG2190, GG2191, GG2187, GG2185	2023-05-31	2024-03-31
	GK4940, GK4941, GK4942	2023-11-30	2024-03-31
	GK4943, GJ2964, GK1234, GJ7300, GJ7303, GL0349, GL6161, GL0350, GL0351, GL0352, GJ2965	2023-12-31	2024-03-31
GM7360, GM7359, GM7358, GM7357	2024-01-31	2024-03-31	
GR2928	2024-01-31	2024-05-31	
<b>PAXLOVID (150 mg nirmatrelvir; 100 mg ritonavir)</b>	GJ4599	2023-03-31	2024-01-31
	GG3564	2023-05-31	2024-03-31
	GP9562, GP9563	2023-11-30	2024-05-31

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

